Notch signaling and efficacy of PD-1/PD-L1 blockade in relapsed small cell lung cancer
Immune checkpoint blockade (ICB) benefits only a small subset of patients with small cell lung cancer (SCLC) and the mechanisms driving benefit are poorly understood. Here, the authors show that elevated Notch signaling predicts clinical benefit in ICB in relapsed SCLC.
Main Authors: | , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-06-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-021-24164-y |